Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Telomir Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Telomir Pharmaceuticals, Inc.’s stock price such as:

• Telomir Pharmaceuticals, Inc.’s current stock price and volume
• Why Telomir Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for TELO from analysts
• TELO’s stock price momentum as measured by its relative strength

About Telomir Pharmaceuticals, Inc. (TELO)

Before we jump into Telomir Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson’s disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer’s disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.

Want to learn more about Telomir Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Telomir Pharmaceuticals, Inc..

Telomir Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, Telomir Pharmaceuticals, Inc.’s stock price was $1.160.

Telomir Pharmaceuticals, Inc. is 0% from its previous closing price of $1.160.

During the last market session, Telomir Pharmaceuticals, Inc.’s stock traded between $1.160 and $1.190. Currently, there are approximately 60.84 million shares outstanding for Telomir Pharmaceuticals, Inc..

Telomir Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Telomir Pharmaceuticals, Inc. Stock Price History

Telomir Pharmaceuticals, Inc.’s (TELO) price is currently up 3.57% so far this month.

During the month of September, Telomir Pharmaceuticals, Inc.’s stock price has reached a high of $1.190 and a low of $1.085.

Over the last year, Telomir Pharmaceuticals, Inc. has hit prices as high as $2.091 and as low as $0.888. Year to date, Telomir Pharmaceuticals, Inc.’s stock is down 12.78%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Telomir Pharmaceuticals, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there were analysts who downgraded Telomir Pharmaceuticals, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Telomir Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Telomir Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Telomir Pharmaceuticals, Inc. (TELO) by visiting AAII Stock Evaluator.

Relative Price Strength of Telomir Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, Telomir Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of -7.07%, which translates to a Momentum Score of 29 and is considered to be Weak.

Want to learn more about how Telomir Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Telomir Pharmaceuticals, Inc. Stock Price: Bottom Line

As of September 4, 2026, Telomir Pharmaceuticals, Inc.’s stock price is $1.160, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Telomir Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.